Antimicrobial agents and chemotherapy
Authors: Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG, Wall A, Wiegand K, Chambers HF, Antibacterial Resistance Leadership Group
Rheumatology (Oxford, England)
Authors: Barraclough M, Erdman L, Diaz-Martinez JP, Knight A, Bingham K, Su J, Kakvan M, Mu?oz Grajales C, Tartaglia MC, Ruttan L, Wither J, Choi MY, Bonilla D, Appenzeller S, Parker B, Goldenberg A, Katz P, Beaton D, Green R, Bruce IN, Touma Z
Cancers
Authors: Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J
Journal of patient safety
Authors: Schmajuk G, Montgomery A, Tarasovsky G, Li J, Hauser RG, Rozenberg-Ben-Dror K, Whooley MA
Current opinion in HIV and AIDS
Authors: Kerkhoff AD, Muiruri C, Geng EH, Hickey MD
Journal of diabetes science and technology
Authors: Yeung AM, Huang J, Nguyen KT, Xu NY, Hughes LT, Agrawal BK, Ejskjaer N, Klonoff DC
Journal of the American Heart Association
Authors: Minhas AS, Leucker TM, Goerlich E, Soleimani-Fard A, Schär M, Ziogos E, Miller E, Gerstenblith G, Hays AG
Volume 11 of Issue 23 | Journal of the American Heart Association
Authors: Matthia EL, Setteducato ML, Elzeneini M, Vernace N, Salerno M, Kramer CM, Keeley EC
Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy representing key pathologic processes including wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction, in addition to their clinical significance.
View on PubMed
Frontiers in Epidemiology
Authors: Hernandez AL, Weatherly CS, Gonzalez R, Farhat S, Da Costa M, Calderon J, Kauffman J, Akha AS, Hilton JF, Palefsky JM
Diagnosis (Berlin, Germany)
Authors: Rosner BI, Zwaan L, Olson APJ